Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer

The objective of this study was to compare the efficacy of abiraterone acetate with that of bicalutamide in combination with gonadotropin-releasing hormone (GnRH) antagonist treatment for patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). A total of 149 patients with mHSPC...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Takashi, Shiraishi, Takumi, Ito, Saya, Ohashi, Munehiro, Matsugasumi, Toru, Yamada, Yasuhiro, Fujihara, Atsuko, Hongo, Fumiya, Okihara, Koji, Ukimura, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115638/
https://www.ncbi.nlm.nih.gov/pubmed/33980956
http://dx.doi.org/10.1038/s41598-021-89609-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115638/
https://www.ncbi.nlm.nih.gov/pubmed/33980956
http://dx.doi.org/10.1038/s41598-021-89609-2

Ejemplares similares